Skip to main content


Log in

Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®

  • Neurology and Preclinical Neurological Studies - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript


Botulinum toxin (BT) therapy is the treatment of choice for blepharospasm (BPS). Currently available BT type A drugs include Botox®, Dysport® and Xeomin®. Until now, there are few long-term studies on BT therapy for BPS. This is the first long-term study comparing all three major BT drugs. We collected treatment, efficacy and adverse effect data on BPS patients treated with either Botox®, Dysport® or Xeomin® for at least eight consecutive treatments. Two hundred and eighty-eight patients (208 females, 80 males, age 62 ± 12 years) were included in this study. The treatment time was 11.2 ± 4.1 years covering 10,701 injection series. Doses were 47 ± 10 MU for Botox®, 120 ± 35 MU for Dysport® and 62 ± 11 MU for Xeomin® (Botox® dose vs Xeomin® dose: p < 0.001, unpaired t test). 85 % of all patients had stable doses. The onset of the therapeutic effect was after 6.1 ± 3.3 days and its duration lasted 10.2 ± 3.5 weeks. The Global Clinical Improvement (GCI, 0 = no, 1 = slight, 2 = moderate, 3 = marked improvement in severity and function) as estimated by the patient was 2.5 ± 0.6. It was stable in 90 % of the patients. Adverse effect frequency was 3.0 % (ptosis 2.3 %, dry eye 0.5 %, diplopia 0.2 %). None of these findings was significantly different between Botox®, Dysport® and Xeomin®. Our study, one of the largest studies on BT therapy of BPS and the study with the longest follow-up, confirms that BT therapy produces robust clinical improvement which is stable throughout the treatment time. Therapeutic effects start after 6.1 days and last for about 10 weeks before they start to vanish. With this, they are approximately 2 weeks shorter than the recommended inter-injection interval. Adverse effects were rare, mild and always transient. BT therapy is a safe and effective treatment for BSP. Shorter inter-injection intervals may improve therapeutic results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  • Ababneh OH, Cetinkaya A, Kulwin DR (2014) Long-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol 42(3):254–261

  • Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A (2013) Dystonia rating scales: critique and recommendations. Mov Disord 28:874–883

    Article  PubMed Central  PubMed  Google Scholar 

  • Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo FS, Albanese A (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 15:224–231

    Article  CAS  PubMed  Google Scholar 

  • Calace P, Cortese G, Piscopo R, Della VG, Gagliardi V, Magli A, De BT (2003) Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 13:331–336

    CAS  PubMed  Google Scholar 

  • Cillino S, Raimondi G, Guepratte N, Damiani S, Cillino M, Di PF, Casuccio A (2010) Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye (Lond) 24:600–607

    Article  CAS  Google Scholar 

  • Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA (2013) Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol 156:173–177

    Article  CAS  PubMed  Google Scholar 

  • Dressler D (2009) Routine use of Xeomin in patients pre-treated with Botox: long term results. Eur J Neurol 16(Suppl 2):2–5

    Article  PubMed  Google Scholar 

  • Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin((R))): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385–389

    Article  CAS  PubMed  Google Scholar 

  • Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38

    Article  CAS  PubMed  Google Scholar 

  • Dressler D, Bigalke H (2004) Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 52:132–135

    Article  CAS  PubMed  Google Scholar 

  • Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox(R)) and incobotulinumtoxinA (Xeomin (R)) in an LD50 assay. J Neural Transm 119:13–15

    Article  CAS  PubMed  Google Scholar 

  • Dressler D, Tacik P, Adib SF (2014a) Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(R)) and incobotulinumtoxinA (Xeomin (R)). J Neural Transm 121:29–31

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Dressler D, Tacik P, Adib SF (2014b) Botulinum toxin therapy for cervical dystonia: duration of therapeutic effects. J Neural Transm. doi:10.1007/s00702-014-1253-8

  • Dutton JJ, Buckley EG (1988) Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 95:1529–1534

    Article  CAS  PubMed  Google Scholar 

  • Dutton JJ, Fowler AM (2007) Botulinum toxin in ophthalmology. Surv Ophthalmol 52:13–31

    Article  PubMed  Google Scholar 

  • Frevert J (2009) Xeomin is free from complexing proteins. Toxicon 54:697–701

    Article  CAS  PubMed  Google Scholar 

  • Frueh BR, Callahan A, Dortzbach RK, Wilkins RB, Beale HL, Reitman HS, Watson FR (1976) The effects of differential section of the VIITH nerve on patients with intractable blepharospasm. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 81:OP595–OP602

    CAS  PubMed  Google Scholar 

  • Gil PC, Rodriguez Sanz MF, Berrocal IN, Castrillo SA, Gutierrez RR, Zamora Garcia MI, Mendoza RA, Duarte Garcia-Luis J (2013) Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin. Neurologia 28:131–136

    Article  Google Scholar 

  • Gill HS, Kraft SP (2010) Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can J Neurol Sci 37:631–636

    Article  PubMed  Google Scholar 

  • Grandas F, Elston J, Quinn N, Marsden CD (1988) Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767–772

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288–1293

    Article  PubMed  Google Scholar 

  • Jankovic J, Ford J (1983) Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 13:402–411

    Article  CAS  PubMed  Google Scholar 

  • Kenney C, Jankovic J (2008) Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 115:585–591

    Article  CAS  PubMed  Google Scholar 

  • Kollewe K, Mohammadi B, Dengler R, Dressler D (2010) Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm 117:759–763

    Article  PubMed  Google Scholar 

  • Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31:463–466

    Article  CAS  PubMed  Google Scholar 

  • Mohammadi B, Balouch SA, Dengler R, Kollewe K (2010) Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients. Neurol Res 32:309–313

    Article  CAS  PubMed  Google Scholar 

  • Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ III (1988) Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3:188–194

    Article  CAS  PubMed  Google Scholar 

  • Rollnik JD, Matzke M, Wohlfarth K, Dengler R, Bigalke H (2000) Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol 43:9–12

    Article  CAS  PubMed  Google Scholar 

  • Silveira-Moriyama L, Goncalves LR, Chien HF, Barbosa ER (2005) Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq Neuropsiquiatr 63:221–224

    Article  PubMed  Google Scholar 

  • Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH (2013) Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin (R)) injections in blepharospasm. J Neural Transm 120:1345–1353

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Vogt T, Lussi F, Paul A, Urban P (2008) Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Nervenarzt 79:912–917

    Article  CAS  PubMed  Google Scholar 

  • Wabbels B, Jost WH, Roggenkamper P (2011) Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neural Transm 118:925–943

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Katja Kollewe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kollewe, K., Mohammadi, B., Köhler, S. et al. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport® . J Neural Transm 122, 427–431 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: